Long‐Term Response to Intermittent Binimetinib in Patients with NRAS ‐Mutant Melanoma
Published 2020 View Full Article
- Home
- Publications
- Publication Search
- Publication Details
Title
Long‐Term
Response to Intermittent Binimetinib in Patients with
NRAS
‐Mutant Melanoma
Authors
Keywords
-
Journal
ONCOLOGIST
Volume -, Issue -, Pages -
Publisher
Wiley
Online
2020-09-21
DOI
10.1634/theoncologist.2019-0656
References
Ask authors/readers for more resources
Related references
Note: Only part of the references are listed.- Pulsatile MEK Inhibition Improves Anti-tumor Immunity and T Cell Function in Murine Kras Mutant Lung Cancer
- (2019) Hyejin Choi et al. Cell Reports
- LBA69Combination treatment with cobimetinib (C) and atezolizumab (A) vs pembrolizumab (P) in previously untreated patients (pts) with BRAFV600 wild type (wt) advanced melanoma: Primary analysis from the phase III IMspire170 trial
- (2019) A M Arance et al. ANNALS OF ONCOLOGY
- In Vivo E2F Reporting Reveals Efficacious Schedules of MEK1/2–CDK4/6 Targeting and mTOR–S6 Resistance Mechanisms
- (2018) Jessica L.F. Teh et al. Cancer Discovery
- MEK inhibitors for the treatment of NRAS mutant melanoma
- (2018) Saro Sarkisian et al. Drug Design Development and Therapy
- Binimetinib versus dacarbazine in patients with advanced NRAS -mutant melanoma (NEMO): a multicentre, open-label, randomised, phase 3 trial
- (2017) Reinhard Dummer et al. LANCET ONCOLOGY
- MEK inhibition and immune responses in advanced melanoma
- (2017) Reinhard Dummer et al. OncoImmunology
- MAP Kinase Inhibition Promotes T Cell and Anti-tumor Activity in Combination with PD-L1 Checkpoint Blockade
- (2016) Peter J.R. Ebert et al. IMMUNITY
- Overall Survival and Durable Responses in Patients WithBRAFV600–Mutant Metastatic Melanoma Receiving Dabrafenib Combined With Trametinib
- (2016) Georgina V. Long et al. JOURNAL OF CLINICAL ONCOLOGY
- Co-existence of BRAF and NRAS driver mutations in the same melanoma cells results in heterogeneity of targeted therapy resistance
- (2016) Marieke I.G. Raaijmakers et al. Oncotarget
- Targeting the MAPK and PI3K pathways in combination with PD1 blockade in melanoma
- (2016) Marcel A. Deken et al. OncoImmunology
- Genomic Classification of Cutaneous Melanoma
- (2015) Rehan Akbani et al. CELL
- The BRAF and MEK Inhibitors Dabrafenib and Trametinib: Effects on Immune Function and in Combination with Immunomodulatory Antibodies Targeting PD-1, PD-L1, and CTLA-4
- (2015) L. Liu et al. CLINICAL CANCER RESEARCH
- Microphthalmia-associated transcription factor in melanoma development and MAP-kinase pathway targeted therapy
- (2015) Claudia Wellbrock et al. Pigment Cell & Melanoma Research
- The epigenetic modifier EZH2 controls melanoma growth and metastasis through silencing of distinct tumour suppressors
- (2015) Daniel Zingg et al. Nature Communications
- The Evolution of Melanoma Resistance Reveals Therapeutic Opportunities
- (2013) M. D. Thakur et al. CANCER RESEARCH
- MEK162 for patients with advanced melanoma harbouring NRAS or Val600 BRAF mutations: a non-randomised, open-label phase 2 study
- (2013) Paolo A Ascierto et al. LANCET ONCOLOGY
- Modelling vemurafenib resistance in melanoma reveals a strategy to forestall drug resistance
- (2013) Meghna Das Thakur et al. NATURE
- NRAS mutant melanoma: biological behavior and future strategies for therapeutic management
- (2012) I V Fedorenko et al. ONCOGENE
- A proliferative melanoma cell phenotype is responsive to RAF/MEK inhibition independent of BRAF mutation status
- (2010) Marie C. Zipser et al. Pigment Cell & Melanoma Research
Discover Peeref hubs
Discuss science. Find collaborators. Network.
Join a conversationAsk a Question. Answer a Question.
Quickly pose questions to the entire community. Debate answers and get clarity on the most important issues facing researchers.
Get Started